Fluticasone propionate/formoterol fumarate in children aged ≥ 5 years with asthma: a profile of its use
AbstractThe fluticasone propionate/formoterol fumarate (hereafter fluticasone/formoterol) 50/5 µg pressurized metered-dose inhaler (pMDI) [Flutiform®] is a fixed-dose combination of an inhaled corticosteroid (ICS) and a long-acting β2-adrenoceptor agonist (LABA) for the regular treatment of asthma where regular use of an ICS and a LABA combination product is appropriate. In the EU, the fluticasone/formoterol 50/5 µg pMDI is recommended for use in adults, adolescents and children aged ≥ 5 years, with the latter being a recent expansion of the indicated population and the focus of this review. Fluticasone/formot...
Source: Drugs and Therapy Perspectives - November 3, 2019 Category: Drugs & Pharmacology Source Type: research
Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma
Journal of Aerosol Medicine and Pulmonary Drug Delivery, Ahead of Print. (Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery)
Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery - October 20, 2019 Category: Respiratory Medicine Authors: Dik Ng Edward M. Kerwin Martha V. White S. David Miller Scott Haughie Jonathan K. Ward Richard Allan Source Type: research
Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis
ConclusionsThe results of this meta-analysis show that LABA/LAMA combinations are consistently more effective than ICS/LABA FDCs for most of the evaluated outcomes. However, differences have also been observed between FDCs belonging to the same class. Across the investigated LABA/LAMA FDCs, glycopyrronium/indacaterol revealed a consistent and robust efficacy profile. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 20, 2019 Category: Respiratory Medicine Source Type: research
Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs.
Conclusions: In this real-world study, patients initiating FF/VI had better adherence and lower risk of discontinuing treatment versus B/F or FP/SAL, suggesting that once-daily ICS/LABA treatment might improve adherence and persistence compared with twice-daily alternatives.
PMID: 31607180 [PubMed - as supplied by publisher] (Source: Journal of Asthma)
Source: Journal of Asthma - October 16, 2019 Category: Respiratory Medicine Tags: J Asthma Source Type: research
Erratum
In the article “Global initiative for Asthma 2016–derived asthma control with fluticasone propionate and salmeterol. A Gaining Optimal Asthma Control (GOAL) study reanalysis” by Bateman ED et al (Ann Allergy Asthma Immunol;2019:57-63.e2) the legend to Figure 2 was incorrect. The correct legend should be: P roportion of patients who achieved well-controlled or partly-controlled asthma, or well-controlled asthma by week (intent-to-treat population). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - September 30, 2019 Category: Allergy & Immunology Tags: Erratum Source Type: research
Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies
Journal of Aerosol Medicine and Pulmonary Drug Delivery, Ahead of Print. (Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery)
Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery - July 30, 2019 Category: Respiratory Medicine Authors: Scott Haughie Richard Allan Nolan Wood Jon Ward Source Type: research
Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD
No studies have investigated genetic effects on quality of life (QoL) measurements like improvements in the St George's Respiratory Questionnaire (SGRQ) scores for chronic obstructive pulmonary disease treatments with fluticasone propionate/salmeterol (FSC). Therefore, in addition to testing genetic effects on change from baseline in trough forced expiratory volume in 1 s (FEV1), genetic associations that may predict SGRQ response to FSC treatment were investigated in this analysis. (Source: Respiratory Medicine)
Source: Respiratory Medicine - June 27, 2019 Category: Respiratory Medicine Authors: Lynn D. Condreay, Xiaoyan A. Qu, Julie Anderson, Chris Compton, Soumitra Ghosh Tags: Short communication Source Type: research
A Dose-Response Study Examining the Use of Methacholine Challenge to Demonstrate Local Therapeutic Equivalence of the Salmeterol Component of Generic Inhaled Fluticasone Propionate/Salmeterol Combination Products
Journal of Aerosol Medicine and Pulmonary Drug Delivery, Ahead of Print. (Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery)
Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery - June 27, 2019 Category: Respiratory Medicine Authors: Richard Allan Scott Haughie Richard Ahrens Sachinkumar Singh Jon Ward Source Type: research
A Dose –Response Study to Examine the Methodology for Demonstrating the Local Therapeutic Equivalence of the Fluticasone Propionate Component of an Orally Inhaled Combination Therapy of Fluticasone Propionate/Salmeterol Dry Powder
Journal of Aerosol Medicine and Pulmonary Drug Delivery, Ahead of Print. (Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery)
Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery - June 27, 2019 Category: Respiratory Medicine Authors: Richard Allan Scott Haughie Edward Kerwin Jon Ward Source Type: research
Tiotropium/Olodaterol: A Review in COPD
AbstractTiotropium/olodaterol (Stiolto® Respimat®; Spiolto® Respimat®) is an inhaled fixed-dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenergic agonist olodaterol. It is available in several countries, including the USA, Japan, China and those of the EU, where it is indicated for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy of tiotropium/olodaterol 5/5 μg/day in patients with COPD was evaluated in phase III or IV trials of 6–52 weeks’ duration. Tiot...
Source: Drugs - May 21, 2019 Category: Drugs & Pharmacology Source Type: research
Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials
ConclusionUMEC/VI consistently demonstrated improved lung function versus TIO and FP/SAL across age and airflow limitation severity subgroups, with no safety concerns, indicating that UMEC/VI provides no loss in efficacy or additional safety concerns for both elderly patients with COPD and patients with severe/very severe airway limitation. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - May 14, 2019 Category: Respiratory Medicine Source Type: research
Single Inhaler LABA/LAMA for COPD
Conclusions of that meta-analysis should be interpreted with great caution because of differences in population studied, and differences in primary and co-primary outcomes.
A recent comparison meta-analysis was not conclusive due to the heterogeneity of phase III studies and the few number of studies for some of the investigated drugs (ACL/FF and GLY/FF in particular), but confirmed that dual bronchodilation was always more effective than LABA or LAMA alone, both in lung function and quality of life indices (Calzetta et al., 2016). This meta-analysis suggested that among the different FDCs may exist a gradient of effectiv...
Source: Frontiers in Pharmacology - April 24, 2019 Category: Drugs & Pharmacology Source Type: research
GINA 2016-derived asthma control with fluticasone propionate/salmeterol: a Gaining Optimal Asthma controL (GOAL) study reanalysis
The two key long-term goals of asthma management are to improve symptom control and reduce the risk of poor outcomes, including exacerbations.1 For patients, quality of life depends upon the overall level of asthma control achieved,2-4 which may encompass the frequency and severity of a number of asthma measures, including symptoms, lung function, and exacerbations.5 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 23, 2019 Category: Allergy & Immunology Authors: Eric D. Bateman, William Busse, S øren E. Pedersen, Jean Bousquet, Shaoguang Huang, Xin Zhou, Nadeem Gul, Sally Hollis, Michael Gibbs Source Type: research
GINA 2016-derived asthma control with fluticasone propionate/salmeterol: a Gaining Optimal Asthma controL (GOAL) study reanalysis.
PMID: 31028894 [PubMed - as supplied by publisher] (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 23, 2019 Category: Allergy & Immunology Authors: Bateman ED, Busse W, Pedersen SE, Bousquet J, Huang S, Zhou X, Gul N, Hollis S, Gibbs M Tags: Ann Allergy Asthma Immunol Source Type: research
Global Initiative for Asthma 2016 –derived asthma control with fluticasone propionate and salmeterol
In 2004, the landmark Gaining Optimal Asthma Control (GOAL) study demonstrated that most patients can achieve asthma control through sustained treatment and that adding a long-acting β2-adrenoreceptor agonist to an inhaled corticosteroid (ICS) is more effective than ICS alone in this regard. Definitions of asthma control have since evolved, and the consequent implications for the GOAL study findings are unclear. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 23, 2019 Category: Allergy & Immunology Authors: Eric D. Bateman, William Busse, S øren E. Pedersen, Jean Bousquet, Shaoguang Huang, Xin Zhou, Nadeem Gul, Sally Hollis, Michael Gibbs Tags: Original Article Source Type: research
